# A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

> **NCT01973309** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Vantictumab combined with paclitaxel

## Key facts

- **NCT ID:** NCT01973309
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973309, "A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01973309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*